1
|
Zilla P, Brink J, Human P, Bezuidenhout D. Prosthetic heart valves: Catering for the few. Biomaterials 2008; 29:385-406. [DOI: 10.1016/j.biomaterials.2007.09.033] [Citation(s) in RCA: 125] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2007] [Accepted: 09/23/2007] [Indexed: 01/17/2023]
|
2
|
Misawa Y, Taguchi M, Aizawa K, Takahashi H, Sakano Y, Kaminishi Y, Oki SI, Konishi H, Saito T, Kato M. Twenty-Two Year Experience with the Omniscience Prosthetic Heart Valve. ASAIO J 2004; 50:606-10. [PMID: 15672796 DOI: 10.1097/01.mat.0000144366.11737.f0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
This study was designed to evaluate the long-term clinical results of the Omniscience tilting disc valve. Omniscience valves were implanted in 51 patients (mean age, 50 +/- 10 years); 18 had aortic valve, 24 had mitral valve, and 9 had both aortic and mitral valve replacements. Oral warfarin potassium and dipyridamole were prescribed as our anticoagulant therapy. Preoperatively, 42 patients were in New York Heart Association class III or IV, and 23 of 25 surviving patients were in class I or II after operation. There were 2 (3.9%) early deaths and 23 late deaths (3.5 +/- 0.7% per patient-year). Cardiac related mortality including congestive heart failure, sudden death, and thromboembolism, and hemorrhagic complications were seen in 16 patients. Overall survival at 10, 15, and 20 years was 77 +/- 6%, 62 +/- 7%, and 46 +/- 7%, respectively. Thromboembolic complications were seen in 5 patients, for a rate of 0.8 +/- 0.3% per patient-year; similarly, hemorrhagic complications were also seen in 5 patients. Nonstructural prosthetic valve dysfunction was seen in 4 patients, for a rate of 0.6 +/- 0.3% per patient-year, and sudden death was seen in 2, a rate of 0.3 +/- 0.2% per patient-year. The Omniscience prosthesis demonstrated excellent postoperative clinical status with low rates of valve related complications.
Collapse
Affiliation(s)
- Yoshio Misawa
- Division of Cardiovascular Surgery, Jichi Medical School, Tochigi, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Edwards MS, Russell GB, Edwards AF, Hammon JW, Cordell AR, Kon ND. Results of valve replacement with Omniscience mechanical prostheses. Ann Thorac Surg 2002; 74:665-70. [PMID: 12238821 DOI: 10.1016/s0003-4975(02)03720-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND The Omniscience mechanical valve has been the subject of multiple clinical investigations with variable results, including reports of high complication and reoperation rates. METHODS Records of all patients who received Omniscience valves were reviewed, and follow-up interviews were conducted to determine the incidence of valve-related morbidity, mortality, and functional results. Incidence of complications was expressed as events per 100 patient-years follow-up. Survival and freedom from valve-related complications and mortality were calculated using a product limit method. RESULTS Between 1984 and 1988, 192 patients received 213 Omniscience valves [93 mitral (M), 79 aortic (A), and 20 multiple (D) valve replacements]. Perioperative mortality was 9%. The incidence of major valve-related morbidity was as follows: thrombosis, 1.30 M, 0.17 A, 0.72 D; endocarditis, 0.48 M, 0.18 A, 0 D; hemorrhagic, 4.67 M, 2.84 A, 5.00 D; embolic, 2.90 M, 2.27 A, 1.57 D; nonstructural dysfunction, 1.66 M, 1.08 A, 2.27 D; reoperation, 4.02 M, 1.99 A, 6.48 D. All explanted valves (n = 43) were examined, and 40% (n = 17) were found to have limited disc excursion in the absence of thrombus. Freedom from valve-related morbidity, mortality, or reoperation at 10 years was 22% for mitral, 39% for aortic, and 17% for multivalve replacements. At follow-up, only 73% of patients were New York Heart Association class I or II. Five- and 10-year estimated survivals were 72% and 55% for M, 80% and 51% for A, and 65% and 50% for D replacements. CONCLUSIONS Use of the Omniscience valve provided poor functional improvement and a significant incidence of valve-related complications, including the need for reoperation.
Collapse
Affiliation(s)
- Matthew S Edwards
- Department of Cardiothoracic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA
| | | | | | | | | | | |
Collapse
|
4
|
Misawa Y, Fuse K, Saito T, Konishi H, Oki SI. Fourteen year experience with the omnicarbon prosthetic heart valve. ASAIO J 2001; 47:677-82. [PMID: 11730210 DOI: 10.1097/00002480-200111000-00021] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The Omnicarbon prosthetic valve was implanted in 168 patients (mean age, 53 years); 84 had aortic valve replacement (AVR), 57 had mitral valve replacement (MVR), and 27 had both aortic and mitral valve replacement (DVR). The mean follow-up period was 6.8 years, with a maximum of 13.7 years. Three patients (1.8%) were lost to follow-up. There were 4 (2.4%) early deaths and 26 late deaths. Survival at 10 years was 76% in the AVR and MVR groups, and 85% in the DVR group. Freedom from thromboembolism at 10 years was 94% in the AVR group, 80% in the MVR group, and 92% in the DVR group. Freedom from hemorrhagic complications at 10 years was 86% in the AVR group and 92% in the MVR group. At 10 years, 97% in the AVR group and 96% in the MVR group were free from endocarditis. One patient in the DVR group suffered a paravalvular leak. At 10 years, 97% in the AVR group and 95% in the MVR group had not needed reoperation. Elevation of the postoperative serum lactate dehydrogenase levels were acceptable in the three groups. In conclusion, the Omnicarbon prosthetic valve has shown excellent long-term clinical results.
Collapse
Affiliation(s)
- Y Misawa
- Department of Thoracic and Cardiovascular Surgery, Jichi Medical School, Tochigi, Japan
| | | | | | | | | |
Collapse
|
5
|
Altman R. Controversies in Antithrombotic Therapy in Cardiovascular Diseases. Clin Appl Thromb Hemost 1998. [DOI: 10.1177/107602969800400105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Antithrombotic treatment became an important point in human medical treatment. Dicoumarols, heparin, aspi rin, and more recently, direct antithrombins and platelet glyco protein IIb/IIIa receptor blockers are the most frequent medi cations used as antithrombotics. The role of these drugs in the treatment of cardiovascular diseases remains controversial. Low-dose aspirin (80-100 mg/day) should be used for second ary prevention in patients with a history of coronary disease. Primary prevention in patients with no risk factors is not rec ommended. Studies using oral anticoagulant therapy indicated that long-term therapy achieves substantial benefit in arterial complications in patient survivors of myocardial infarction. Combined therapy of aspirin and a higher dose of oral antico agulant than that used in the CARS trial seem necessary after myocardial infarction, and further studies should be under taken. In the treatment of unstable angina, the combined use of aspirin and unfractioned heparin (UFH) is widely accepted. Low molecular weight heparin (LMWH) was also proposed for the treatment of these patients, but the beneficial effect of LMWH over UFH is a matter of discussion, and more prospec tive studies with different LMWHs should be undertaken be fore reaching a definitive answer. The use of hirudin needs additional studies because its superiority over heparin is un- proved. The initial clinical experience with blockers/inhibitors of platelet glycoprotein IIb/IIIa receptors has been promising, although some increase of bleeding was reported. According to published trials on the use of antiplatelet drugs and antithrom botic therapy in the prevention of acute closure after PTCA or after stent implantation, antithrombotic therapy decreased the incidence of abrupt closure or reocclusion at 30 days postan gioplasty, but neither antiplatelet agents nor other pharmaco logical agents have been shown to reduce significantly the rate of restenosis. Finally, oral anticoagulant in a target INR of 2.0 to 3.0 together with aspirin 100 mg/day provide good protec tion from thromboembolism and diminish the rate of minor bleeding complications in patients with cardiac valve replace ment.
Collapse
Affiliation(s)
- Raul Altman
- Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
6
|
|
7
|
Akins CW. Reply. Ann Thorac Surg 1996. [DOI: 10.1016/s0003-4975(96)80897-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Mikhail AA. Omniscience valve evolution and literature. Ann Thorac Surg 1996; 62:624-6. [PMID: 8694649 DOI: 10.1016/s0003-4975(96)80896-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
9
|
Abstract
Mechanical cardiac valvular prostheses continue to be more popular than bioprostheses for heart valve replacement operations. Five different brands of mechanical heart valves are now approved for implantation in the United States: Starr-Edwards models 1260 and 6120, Medtronic-Hall, St. Jude Medical, Omniscience, and CarboMedics. Each model of mechanical valve has certain positive and negative attributes, but none is functionally mechanically perfect. A review of the published long term results with these valves favors the Medtronic-Hall and St. Jude Medical valves. A new method of assessing the thrombogenic potential and requirement for anticoagulation of the different mechanical valves, namely the composite thromboembolism and bleeding index, is proposed. Evaluation of the new index demonstrates a modest advantage for the Medtronic-Hall valve, particularly in the aortic position.
Collapse
Affiliation(s)
- C W Akins
- Cardiac Surgical Unit, Massachusetts General Hospital, Boston 02114, USA
| |
Collapse
|
10
|
Georgiadis D, Grosset DG, Kelman A, Faichney A, Lees KR. Prevalence and characteristics of intracranial microemboli signals in patients with different types of prosthetic cardiac valves. Stroke 1994; 25:587-92. [PMID: 8128512 DOI: 10.1161/01.str.25.3.587] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND AND PURPOSE Transcranial Doppler detection of microemboli is widely described, but there is no clear evidence of the clinical significance or nature of the embolic material in vivo. Thromboembolism is a major cause of morbidity in patients with prosthetic cardiac valves. We undertook this study to evaluate the prevalence and the acoustic characteristics of microembolic signals in three groups of patients with different prosthetic valves. METHODS One hundred seventy-nine patients with prosthetic cardiac valves (85 Björk-Shiley, 56 Medtronic-Hall, and 38 Carpentier-Edwards) and 25 normal subjects were examined using transcranial Doppler. Monitoring time was 30 minutes over the right middle cerebral artery. RESULTS The prevalence and numbers of embolic signals were significantly higher in patients with Björk-Shiley compared with those with Medtronic-Hall and Carpentier-Edwards valves (89% versus 50% and 53%, respectively; P < .001, chi 2; 156 [112, 204] versus 2 [1, 4] and 2 [1, 4] signals/h, respectively; median [95% nonparametric confidence interval], both P < .001, multiple comparisons, Bonferroni correction). The signal intensity was significantly higher in patients with Björk-Shiley and Medtronic-Hall valves than patients with Carpentier-Edwards valves (2435 [2345, 2527] and 2120 [1745, 2483] versus 225 [184, 287] power units, median [95% confidence interval], both P < .001). No correlation was found between embolic signal numbers and clinical parameters including history of neurological deficit, cardiac rhythm, duration of artificial valve, previous cardiac operations, or intensity of anticoagulation. Embolic signals were not detected in any of the control subjects. CONCLUSIONS Our data showed that the prevalence, quantity, and acoustic characteristics of Doppler embolic signals differ in patients having three different types of prosthetic heart valves. However, no correlation with clinical parameters was identified.
Collapse
Affiliation(s)
- D Georgiadis
- University Department of Medicine, Western Infirmary, Glasgow, UK
| | | | | | | | | |
Collapse
|
11
|
Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329:696-702. [PMID: 8135917 DOI: 10.1056/nejm199309023291005] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Patients receiving long-term anticoagulant therapy may be subject to unnecessary risks of bleeding or thromboembolism because of variability in the commercial thromboplastins used to determine prothrombin time and consequent uncertainty about the actual intensity of anticoagulation. METHODS We explored the effect of this uncertainty on the benefits and risks of anticoagulation in patients with prosthetic heart valves, using models of thromboembolic and hemorrhagic complications as a function of the intensity of anticoagulation, with quality-adjusted life expectancy and average variable costs used to describe outcomes. RESULTS Anticoagulation provides a striking benefit for patients whose treatment is conducted within the recommended range of the international normalized ratio (INR)--i.e., 2.5 to 3.5--but if uncertainty about the laboratory results causes the intensity of anticoagulation to fall outside this range, the gain becomes smaller. Uncertainty about the true intensity of anticoagulation may reduce the potential gain in life expectancy, adjusted for quality of life, by more than half and may increase the ratio of costs to effectiveness to almost five times the optimal value. Variability in the intensity of anticoagulation is even greater if older recommendations advocating a higher level of anticoagulation are followed. CONCLUSIONS Uncertainty about the sensitivities of the commercially available thromboplastins used in the United States can have important clinical and economic effects. This problem could be eliminated if clinical laboratories uniformly reported the intensity of anticoagulation as the INR, by adjusting prothrombin-time ratios for variability in thromboplastins.
Collapse
Affiliation(s)
- M H Eckman
- Division of Clinical Decision Making, New England Medical Center, Boston, MA 02111
| | | | | |
Collapse
|
12
|
|
13
|
Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992; 102:445S-455S. [PMID: 1395828 DOI: 10.1378/chest.102.4_supplement.445s] [Citation(s) in RCA: 84] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
14
|
|
15
|
Akalin H, çorapçioğlu ET, özyurda Ü, Uçanok K, Uysalel A, Kaya B, Eren NT, Erol Ç. Clinical evaluation of the Omniscience cardiac valve prosthesis. J Thorac Cardiovasc Surg 1992. [DOI: 10.1016/s0022-5223(19)35026-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
|
17
|
Abstract
Mechanical cardiac valvular prostheses currently enjoy a 60% to 40% market-share advantage over tissue prostheses in the United States and worldwide. Only the Starr-Edwards caged Silastic (Dow Corning) ball, Medtronic-Hall, St. Jude Medical, and Omniscience valves remain available in the United States. Although each valve has certain advantages and disadvantages, no design has achieved functional mechanical perfection. Late follow-up of valve-related complications from the literature favors the St. Jude Medical and Medtronic-Hall valves.
Collapse
Affiliation(s)
- C W Akins
- Cardiac Surgical Unit, Massachusetts General Hospital, Boston 02114
| |
Collapse
|
18
|
Invited letter concerning: Anticoagulant plus platelet inhibitor therapy in patients with mechanical valve prostheses: Reply to the Editor. J Thorac Cardiovasc Surg 1991. [DOI: 10.1016/s0022-5223(19)36744-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
19
|
Altman R, Rouvier J, Gurfinkel E, D’Ortencio O, Manzanel R, La Fuente LD, Favaloro RG. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991. [DOI: 10.1016/s0022-5223(19)36724-8] [Citation(s) in RCA: 168] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Vallejo JL, Gonzalez-Santos JM, Albertos J, Riesgo MJ, Bastida ME, Rico MJ, Gonzalez-Diego F, Arcas R. Eight years' experience with the Medtronic-Hall valve prosthesis. Ann Thorac Surg 1990; 50:429-36. [PMID: 2400265 DOI: 10.1016/0003-4975(90)90489-s] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
During the period January 1981 to September 1986, 444 Medtronic-Hall heart valve prostheses were implanted in 351 patients (mean age, 45 +/- 10 years) mainly for rheumatic valve disease (63.2%). Most of the patients were in New York Heart Association functional class III. Concomitant surgical procedures, mainly conservative tricuspid or mitral procedures or coronary artery bypass grafting, were performed in 101 patients (28.7%). Single-valve replacement was performed in 262 patients (74.6%) (aortic in 117 patients, mitral in 143, and tricuspid in 2), double-valve replacement in 85 (24.2%) (mitral and aortic in 83 and mitral and tricuspid in 2), and triple-valve replacement in 4 (1.1%). Hospital mortality was 6.2%. Follow-up was 97.7% complete. The overall actuarial 8-year survival rate was 77.2%. The linearized incidence of valve-related complications was as follows: thromboembolism, 1.5%/patient-year; reoperation, 1.5%/patient-year; endocarditis, 1.25%/patient-year; hemolysis, 0.52%/patient-year; anticoagulant-related hemorrhage, 0.39%/patient-year; and noninfection-related paraprosthetic leak, 0.33%/patient-year. There were no instances of structural failure. We conclude that after 8 years of follow-up, the Medtronic-Hall valve prosthesis has an excellent clinical performance and a low range of valve-related complications.
Collapse
Affiliation(s)
- J L Vallejo
- Department of Cardiac Surgery, General Hospital Gregorio Marañon, School of Medicine, Universidad Complutense, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Morishita Y, Toyohira H, Yuda T, Umebayashi Y, Saigenji H, Hashiguchi M, Uehara K, Taira A. The necessity of reoperation for patients with Bjork-Shiley, St Jude Medical, Hancock and Carpentier-Edwards prostheses. THE JAPANESE JOURNAL OF SURGERY 1990; 20:384-91. [PMID: 2388440 DOI: 10.1007/bf02470821] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The purpose of this study was to determine the criteria of valve selection from the long-term results of Hancock, Carpentier-Edwards, St Jude Medical and Bjork-Shiley prostheses, taking into special account the frequency of reoperation. Reoperations on the Hancock bioprosthesis were performed on six patients for tissue leaflet disruption with an incidence of 2.2 per cent/patient-year. Reoperations on the Carpentier-Edwards bioprosthesis were performed on 24 patients for tissue leaflet disruption in 23 patients and prosthetic valve endocarditis (PVE) in one, with an incidence of 3.8 per cent/patient-year. Reoperations on the Bjork-Shiley prosthesis were performed in two patients for severe hemolysis, with an incidence of 0.32 per cent/patient-year. Reoperations on the St Jude Medical prosthesis were performed on 3 patients, for valve thrombosis in one patient, PVE in one, and hemolysis in one, with an incidence of 0.23 per cent/patient-year. The overall mortality rate was 20 per cent, or 7 patients, and the indications for reoperation affected this. Patients with primary tissue failure had a mortality rate of 10.3 per cent; those with a thrombosed valve, 0 per cent; those with hemolysis, 66.7 per cent; and those with valve infection, 100 per cent. A good chance of survival may be achieved in patients facing prosthetic valve complications by performing reoperation as soon as possible after early detection, since mortality is high following emergency reoperation and in patients with severe symptoms. Currently, we recommend mechanical prostheses for valve replacement except in patients over 70 years old and in younger patients with absolute contraindications to anticoagulative therapy.
Collapse
Affiliation(s)
- Y Morishita
- Second Department of Surgery, Kagoshima University School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Clean site preparation for a prosthesis is mandatory to avoid tissue interference with the prosthesis. Oversizing of a prosthesis is fraught with peril. In all types of prostheses, orientation has importance. A prosthesis is designed with consideration for axial flow. Tilting the valve in implantation will likely result in a dysfunctional valve. The sewing ring serves not as a gasket but as an additional factor that increases the possibilities of success of a properly implanted valve by taking advantage of its naturally compliant features.
Collapse
Affiliation(s)
- R A DeWall
- Wright State University Medical School, Dayton, Ohio
| | | |
Collapse
|
23
|
|
24
|
Starr A, Grunkemeier GL, Fessler CL. Tissue and mechanical valves: mutually advantageous interplay. J Card Surg 1988; 3:437-47. [PMID: 2980047 DOI: 10.1111/jocs.1988.3.3s.437] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
This report is concerned with the dynamic interplay between glutaraldehyde preserved tissue valves (bioprostheses) and mechanical valves. These two classes of valve replacement devices are not competitive, but provide some nonoverlapping characteristic advantages and disadvantages. By proper selection, it may be possible to tailor the kind of device used for a particular patient, thus improving the overall results of bioprosthetic and mechanical valve replacement. Careful selection of patients according to age and the safety of anticoagulation should achieve a series of patients with mechanical and bioprosthetic valves that would be superior to a series in which all patients received a single device. Thus, these devices should be viewed as complimentary rather than competitive since the value of properly matching a prosthesis to the patient will be reflected in improved overall results with each class of prosthesis.
Collapse
Affiliation(s)
- A Starr
- Heart Institute, St. Vincent Hospital and Medical Center, Portland, Oregon
| | | | | |
Collapse
|
25
|
Aris A, Padró JM, Cámara ML, Crexells C, Augé JM, Caralps JM. Clinical and hemodynamic results of cardiac valve replacement with the Monostrut Björk-Shiley prosthesis. J Thorac Cardiovasc Surg 1988. [DOI: 10.1016/s0022-5223(19)35761-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Kadish SL, Lazar EJ, Frishman WH. Anticoagulation in Patients with Valvular Heart Disease, Atrial Fibrillation, or Both. Cardiol Clin 1987. [DOI: 10.1016/s0733-8651(18)30517-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Abstract
A review of articles published since 1979 indicates that thrombotic and bleeding complications account for about 50% of valve-related complications in patients with bioprosthetic aortic and mitral valves and for approximately 75% of the complications in patients with mechanical valves. Although compromised by lack of standard definitions and by variability in reporting and follow-up, the data suggest that the linearized rate of both thrombotic and bleeding complications in patients with aortic bioprostheses is approximately half that for aortic mechanical prostheses (2% versus 4%), but is approximately equal for both bioprostheses and mechanical valves in the mitral position (approximately 4%), and for mechanical and bioprosthetic aortic and mitral valves in combination. However, linearized rates for fatal thrombotic and bleeding events are two to four times higher in patients with mechanical prostheses. The adequacy of warfarin anticoagulation is the most important factor affecting thrombotic and bleeding complications in patients with mechanical valves and over shadows the dubious importance of other phenomena such as atrial fibrillation and left atrial thrombus. Short-term warfarin anticoagulation or the use of long-term platelet inhibitors, or both, do not appear to reduce the incidence of thrombotic complications in patients with aortic bioprostheses but increase bleeding. For mitral bioprostheses, the postoperative use of warfarin for three months or aspirin indefinitely is as effective in preventing thromboembolism as long-term warfarin. Acute prosthetic valve endocarditis is associated with a 13 to 40% incidence of thrombotic complications. Likewise, the recurrence rate of cerebral emboli is high (20-30%) in patients with prosthetic valves who are not anticoagulated. Bioprostheses are strongly preferred for women who wish to bear children; fetal wastage occurs in 25 to 30% of pregnant women with mechanical heart valves who receive either warfarin or heparin, or a combination of the two. Heparin, however, greatly increases the risk of maternal bleeding. In children, the efficacy of platelet inhibitors without warfarin anticoagulation is unproven; nearly all serious strokes occur when warfarin is omitted; and permanent disability from warfarin-related bleeding is rare. All prosthetic cardiac valves initiate coagulation and affect the dynamic equilibrium between activated procoagulants and endogenous anticoagulants. Warfarin is the only available oral exogenous anticoagulant.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- L H Edmunds
- Department of Surgery, University of Pennsylvania, Philadelphia 19104
| |
Collapse
|
28
|
Abstract
Cardiac valve replacement with mechanical prosthetic or bioprosthetic devices enhances patient survival and quality of life. Nevertheless, prosthesis-associated complications are frequent and contribute significantly to outcome. Thromboembolic complications are the most important problems in patients with mechanical valves, necessitating chronic anticoagulation in all patients receiving them. In contrast, patients with bioprosthetic valves, composed of chemically treated animal tissues, generally do not require anticoagulants. However, bioprostheses fail frequently by degeneration, especially that involving cuspal calcification. This paper reviews the pathological and bioengineering considerations in the selection of cardiac prosthetic valves and the management of patients who have received these devices. The significance, morphology, and pathogenesis of the observed major complications and other alterations during function are described in detail. Contemporary investigative trends are summarized, including studies of inhibition of mineralization and other degenerative changes in bioprostheses, improved design rigid mechanical valves with pyrolytic carbon occluders and the development of central-flow, flexible polymeric leaflet valves.
Collapse
Affiliation(s)
- F J Schoen
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115
| |
Collapse
|
29
|
Martinell J, Fraile J, Artiz V, Cortina J, Fresneda P, Rábago G. Reoperations for left-sided low-profile mechanical prosthetic obstructions. Ann Thorac Surg 1987; 43:172-5. [PMID: 3813707 DOI: 10.1016/s0003-4975(10)60390-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
A series of 2,474 hospital survivors of primary mitral, aortic, and double mitral-aortic valve replacement were observed for a cumulative period of 11.945 years (mean, 4.2 years; range, 0.6-14 years). The linearized incidences of reoperations for thrombotic obstructions were 0.33 +/- 0.08% for mitral valve replacement, 0.36 +/- 0.1% for aortic valve replacement, and 0.42 +/- 0.1% for double valve replacement (p = not significant). Forty-one patients (16 mitral, 12 aortic, and 13 double valve replacements) underwent a total of 44 reoperations with a mean interval of 36 +/- 29 months (range, 0.25-85 months) between operations. Diagnosis was established invasively only in 13 patients (30%). Hospital mortality at reoperation was 18% (8 patients); 28 patients (63%) required emergency surgery. The choice surgical procedures were thrombectomy for clotted aortic prostheses (18 of 24) and valve replacement for obstructed mitral valves (22 of 25; p less than .001). Rethrombosis occurred in 3 patients (1 aortic and 2 double valve replacements). At hospital admission 17 patients (38%) had prothrombin times outside therapeutic ranges (between 20 to 30% of the normal value). The incidence of reoperations for thrombosis in low-profile mechanical prostheses was unaffected by valvar position and number of prostheses implanted. Rethrombosis occurred only in previously cleaned valves, although its occurrence was not significant. The present results indicate that, as experience is gained in the diagnosis and surgical management of this complication, hospital mortality can be reduced significantly (from 37% to 4%).
Collapse
|
30
|
|